Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of RXRX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Tuesday for Recursion Pharmaceuticals, Inc.
(Updated on Apr 30, 2024)

Sell candidate since Mar 25, 2024 Loss -25.74% PDF

The Recursion Pharmaceuticals, Inc. stock price fell by -4.63% on the last day (Tuesday, 30th Apr 2024) from $8.20 to $7.82. During the last trading day the stock fluctuated 5.93% from a day low at $7.80 to a day high of $8.26. The price has been going up and down for this period, and there has been a 3.3% gain for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -267 thousand shares and in total, 4 million shares were bought and sold for approximately $29.24 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -24.73% during the next 3 months and, with a 90% probability hold a price between $3.91 and $9.47 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

RXRX Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Recursion Pharmaceuticals, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $7.89 and $9.15. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, February 27, 2024, and so far it has fallen -49.61%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Recursion Pharmaceuticals, Inc. stock

Recursion Pharmaceuticals, Inc. finds support from accumulated volume at $7.79 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.462 between high and low, or 5.93%. For the last week, the stock has had daily average volatility of 5.54%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (RXRX) For The Upcoming Trading Day Of Wednesday 1st

For the upcoming trading day on Wednesday, 1st we expect Recursion Pharmaceuticals, Inc. to open at $7.96, and during the day (based on 14 day Average True Range), to move between $7.27 and $8.37, which gives a possible trading interval of +/-$0.553 (+/-7.07%) up or down from last closing price. If Recursion Pharmaceuticals, Inc. takes out the full calculated possible swing range there will be an estimated 14.13% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $7.79 (0.38%) than the resistance at $7.94 (1.53%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Recursion Pharmaceuticals, Inc. stock A Buy?

Recursion Pharmaceuticals, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.680 Sell Candidate Unchanged

Predicted Opening Price for Recursion Pharmaceuticals, Inc. of Wednesday, May 1, 2024

Fair opening price May 1, 2024 Current price
$7.96 ( 1.80%) $7.82

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for RXRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 8.42 7.72 %
R2 8.25 5.46 %
R1 8.14 4.06 %
Current price: 7.82
Support S1 7.78 -0.458 %
S2 7.68 -1.85 %
S3 7.50 -4.11 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 9.37 19.82 %
R2 8.77 12.15 %
R1 7.94 1.53 %
Current price 7.82
Support S1 7.79 -0.384%
S2 7.70 -1.53%
S3 7.35 -6.01%

FAQ

What is the symbol for Recursion Pharmaceuticals, Inc. Stock and on which exchange is it traded?
The symbol for Recursion Pharmaceuticals, Inc. is RXRX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Recursion Pharmaceuticals, Inc. Stock?
Recursion Pharmaceuticals, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Recursion Pharmaceuticals, Inc. Stock?
Recursion Pharmaceuticals, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Recursion Pharmaceuticals, Inc. Stock.

What's the current price of Recursion Pharmaceuticals, Inc. Stock?
As of the end of day on the Apr 30, 2024, the price of an Recursion Pharmaceuticals, Inc. (RXRX) share was $7.82.

What is the 52-week high and low for Recursion Pharmaceuticals, Inc. Stock?
The 52-week high for Recursion Pharmaceuticals, Inc. Stock is $16.75 and the 52-week low is $4.54.

What is the market capitalization of Recursion Pharmaceuticals, Inc. Stock?
As of the Apr 30, 2024, the market capitalization of Recursion Pharmaceuticals, Inc. is 1.887B.

When is the next earnings date for Recursion Pharmaceuticals, Inc.?
The upcoming earnings date for Recursion Pharmaceuticals, Inc. is May 13, 2024.
Click to get the best stock tips daily for free!

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial... RXRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT